ATE204760T1 - Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen - Google Patents

Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen

Info

Publication number
ATE204760T1
ATE204760T1 AT94910226T AT94910226T ATE204760T1 AT E204760 T1 ATE204760 T1 AT E204760T1 AT 94910226 T AT94910226 T AT 94910226T AT 94910226 T AT94910226 T AT 94910226T AT E204760 T1 ATE204760 T1 AT E204760T1
Authority
AT
Austria
Prior art keywords
thymosine
respond
patients
treat hepatitis
hepatitis
Prior art date
Application number
AT94910226T
Other languages
English (en)
Inventor
Paul B Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/027,500 external-priority patent/US6001799A/en
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State filed Critical Alpha 1 Biomedicals Inc
Application granted granted Critical
Publication of ATE204760T1 publication Critical patent/ATE204760T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT94910226T 1993-03-05 1994-03-03 Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen ATE204760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,500 US6001799A (en) 1991-09-13 1993-03-05 Method of treating hepatitis C in non-responders to interferon treatment
PCT/US1994/002320 WO1994020131A1 (en) 1993-03-05 1994-03-03 Method of treating hepatitis c in non-responders to interferon treatment

Publications (1)

Publication Number Publication Date
ATE204760T1 true ATE204760T1 (de) 2001-09-15

Family

ID=21838079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910226T ATE204760T1 (de) 1993-03-05 1994-03-03 Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen

Country Status (17)

Country Link
EP (1) EP0687181B1 (de)
JP (1) JPH06279309A (de)
KR (1) KR100306024B1 (de)
CN (1) CN1072961C (de)
AT (1) ATE204760T1 (de)
AU (1) AU683248B2 (de)
CA (1) CA2157479C (de)
DE (1) DE69428112T2 (de)
DK (1) DK0687181T3 (de)
ES (1) ES2162862T3 (de)
FI (1) FI954127A7 (de)
GR (1) GR3037021T3 (de)
MY (1) MY121198A (de)
NO (1) NO320877B1 (de)
PT (1) PT687181E (de)
SG (1) SG64894A1 (de)
WO (1) WO1994020131A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
CA2418154A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin and pegylated interferon
JP4629033B2 (ja) 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα１によるアスペルギルス感染の治療
JP5441685B2 (ja) * 2006-05-02 2014-03-12 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用
US9034837B2 (en) * 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
AU683248B2 (en) 1997-11-06
AU6275994A (en) 1994-09-26
FI954127L (fi) 1995-09-04
ES2162862T3 (es) 2002-01-16
EP0687181A1 (de) 1995-12-20
FI954127A0 (fi) 1995-09-04
DE69428112T2 (de) 2002-03-21
NO953473L (no) 1995-09-04
CA2157479C (en) 2000-08-08
KR960700741A (ko) 1996-02-24
MY121198A (en) 2006-01-28
PT687181E (pt) 2002-01-30
NO320877B1 (no) 2006-02-06
CA2157479A1 (en) 1994-09-15
WO1994020131A1 (en) 1994-09-15
DE69428112D1 (de) 2001-10-04
NO953473D0 (no) 1995-09-04
CN1092322A (zh) 1994-09-21
GR3037021T3 (en) 2002-01-31
DK0687181T3 (da) 2001-10-01
KR100306024B1 (ko) 2001-11-30
EP0687181B1 (de) 2001-08-29
SG64894A1 (en) 1999-05-25
FI954127A7 (fi) 1995-09-04
JPH06279309A (ja) 1994-10-04
CN1072961C (zh) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE262920T1 (de) Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE88900T1 (de) Konjugate von interferon alpha mit immunglobulinen.
ATE152914T1 (de) Verwendung eines thymosins bei der behandlung von hepatitis c
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
DE69233607D1 (de) Peptide, die die zytotoxische T-Lymphozyte Antwort gegen Hepatitis-B-Virus induzieren
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE68906735D1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
GR3024236T3 (en) Use of leukoregulin for the treatment of animals infected with an envelope-virus
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
MX9708885A (es) Uso de ribavirin e interferon alfa para el tratamiento de hepatitis c.
MY109685A (en) Method for treating hepatitis b carriers with minimal disease
UA30956A (uk) Спосіб лікування алергічного риніту

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification